NewAmsterdam Pharma Company N.V. (NAMS) NASDAQ
31.99
+0.2(+0.63%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
NewAmsterdam Pharma Company N.V.
Address
Gooimeer 2-35
Naarden, 1411 DC
United States of America (the)
Phone
31 35 206 2971
Sector
Healthcare
Industry
Biotechnology
Employees
68
First IPO Date
February 09, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Michael Harvey Davidson FACC Facp. | CEO, President & Executive Director | 1.14M | 1956 |
| Juliette Audet | Chief Strategy & Business Officer | 653,039 | 1987 |
| Louise Kooij | Chief Accounting Officer | 695,419 | 1976 |
| Mayur Amrat Somaiya | Chief Financial Officer | 770,393 | 1974 |
| Douglas F. Kling | Chief Operating Officer | 790,051 | 1973 |
| Johannes Jacob Pieter Kastelein FESC | Founder, Chief Scientific Officer, Member of Executive Board & Director | 808,143 | 1954 |
| Matthew Philippe | Executive VP & Head of Investor Relations | 0 | N/A |
| Chris Deluzio | Executive Vice President of Sales Enterprise Operations | 0 | N/A |
| Bob Rambo | Executive Vice President of Marketing | 0 | N/A |
| Maryellen McQuade | Chief People Officer | 0 | N/A |
| Marc Ditmarsch | Chief Development Officer | 0 | 1967 |
| Michael F. Marino | Chief Legal Officer & Corporate Secretary | 0 | 1976 |
Description
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
